Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 75 countries around the world. CytoSorb® is helping to treat life-threatening conditions in the intensive care unit and cardiac surgery. One major application is the reduction of cytokine storm, with the goal of reducing severe inflammation and serious complications such as organ failure—the leading cause of death in the ICU today, while improving patient outcomes and reducing overall costs of critical care. Another newer application is the reduction of antithrombotic agents, often called “blood thinners,” during open heart surgery, with the goal of reducing unwanted perioperative bleeding.
“There were many factors that led to our selection of CytoSorb® for the Global Product Leadership Award,” said Frost & Sullivan Research Analyst Aish Vivek. “Among the most important was the recognition that this innovative product is surprisingly well-positioned to help solve two long-standing, difficult, and tightly linked fundamental problems with hospital medicine today. These include the high rates of death from common critical illnesses such as sepsis that have no approved treatment, and the resulting staggering costs and losses in critical care that are financially crippling hospital networks and healthcare systems throughout the world.”
Analyst Vivek continued, “Further strengthening CytoSorb’s position is the scarcity of viable competition in the lucrative and vast global critical care and cardiac surgery markets, the strong physician usage and revenue growth, and the external validation from well-respected industry partners, such as Fresenius Medical Care and Terumo Cardiovascular, and government funding agencies. As a high margin, single-use product that works with existing blood pumps in hospitals, CytoSorb® also has an attractive business model that is expected to drive early and significant profitability of the company.”
As CytoSorbents expands its footprint worldwide, it is also pursuing U.S. and Canadian regulatory approval of DrugSorb-ATR to reduce perioperative bleeding risk in patients undergoing coronary artery bypass graft (CABG) open heart surgery on the blockbuster drug, ticagrelor. The first is the pivotal REFRESH 2-AKI registration trial that is currently underway, designed to demonstrate a reduction in post-operative kidney injury after high-risk cardiac surgery. The second is the pivotal STAR-T trial, under the auspices of FDA Breakthrough Designation, to remove the blockbuster drug, ticagrelor, and perioperative bleeding risk, during urgent and emergent cardiothoracic surgery.
CytoSorbents aims to be in the elite company of fast growing medical device companies, with rapid growth, industry leading product gross margins in excess of 80%, and GAAP profitability in the near future, with a ground-breaking therapy that can help to save lives.
CytoSorbents is covered by three analysts from Jefferies, B. Riley, and H.C. Wainwright. The Company is led by an experienced and capable management team focused on growth and increasing shareholder value.
